Ramy Younes

5.7k total citations · 2 hit papers
37 papers, 1.3k citations indexed

About

Ramy Younes is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Ramy Younes has authored 37 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Epidemiology, 17 papers in Hepatology and 16 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Ramy Younes's work include Liver Disease Diagnosis and Treatment (32 papers), Diet, Metabolism, and Disease (13 papers) and Liver Disease and Transplantation (6 papers). Ramy Younes is often cited by papers focused on Liver Disease Diagnosis and Treatment (32 papers), Diet, Metabolism, and Disease (13 papers) and Liver Disease and Transplantation (6 papers). Ramy Younes collaborates with scholars based in Italy, Denmark and United Kingdom. Ramy Younes's co-authors include Elisabetta Bugianesi, Chiara Rosso, Jörn M. Schattenberg, Jacob George, Saeed Esmaili, Vlad Ratziu, Quentin M. Anstee, Salvatore Petta, Pierre Bédossa and Maria Lorena Abate and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Hepatology.

In The Last Decade

Ramy Younes

34 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation

2019 240 citations Saeed Esmaili, Elisabetta Bugianesi et al. profile →
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

2024 217 citations Arun J. Sanyal, Pierre Bédossa et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Ramy Younes

Since Specialization

Citations

This map shows the geographic impact of Ramy Younes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ramy Younes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ramy Younes more than expected).

Fields of papers citing papers by Ramy Younes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ramy Younes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ramy Younes. The network helps show where Ramy Younes may publish in the future.

Co-authorship network of co-authors of Ramy Younes

This figure shows the co-authorship network connecting the top 25 collaborators of Ramy Younes. A scholar is included among the top collaborators of Ramy Younes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ramy Younes. Ramy Younes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association Between Coffee Consumption and Metabolic Syndrome Components Among Saudi Adults 2025 ·Metabolites ·(unknown), (unknown), (unknown), (unknown), (unknown), Ramy Younes, (unknown), (unknown)	1
2	Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report 2025 ·Cureus ·(unknown), Claire Brown, Ramy Younes	0
3	Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis 2024 ·Journal of Hepatology ·Eric Lawitz, Mandy Fraessdorf, Guy Neff, Jörn M. Schattenberg, Mazen Noureddin, Naim Alkhouri, Hans Bernhard Schmid, Charles P. Andrews, István Takács, Samina Ajaz Hussain, Wiebke Fenske, Edward Gane, Azadeh Hosseini‐Tabatabaei, (unknown), Daniel Ferraz de Campos Mazo, Ramy Younes	25
4	SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL 2024 ·Gastroenterology ·Naim Alkhouri, Mandy Fraessdorf, Guy Neff, Jörn M. Schattenberg, Mazen Noureddin, Eric Lawitz, (unknown), Elisabetta Bugianesi, Samina Ajaz Hussain, Philip N. Newsome, Vlad Ratziu, Azadeh Hosseini‐Tabatabaei, Arun J. Sanyal, Ramy Younes	1
5	O7 Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: results from a randomised, double-blind, placebo-controlled phase 2 trial 2024 ·Arun J. Sanyal, Pierre Bédossa, Mandy Fraessdorf, Guy Neff, Eric Lawitz, Elisabetta Bugianesi, Quentin M. Anstee, Samina Ajaz Hussain, Philip N. Newsome, Vlad Ratziu, Azadeh Hosseini‐Tabatabaei, Jörn M. Schattenberg, Mazen Noureddin, (unknown), Ramy Younes	1
6	A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis breakdown → 2024 ·New England Journal of Medicine ·Arun J. Sanyal, Pierre Bédossa, Mandy Fraessdorf, Guy Neff, Eric Lawitz, Elisabetta Bugianesi, Quentin M. Anstee, Samina Ajaz Hussain, Philip N. Newsome, Vlad Ratziu, Azadeh Hosseini‐Tabatabaei, Jörn M. Schattenberg, Mazen Noureddin, Naim Alkhouri, Ramy Younes	217
7	Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease 2023 ·Journal of Clinical Medicine ·Angelo Armandi, Chiara Rosso, Ramy Younes, Diana Julie Leeming, M.A. Karsdal, Gian Paolo Caviglia, (unknown), Daphne D’Amato, Amina Abdulle, (unknown), (unknown), Giorgio Maria Saracco, Davide Giuseppe Ribaldone, Elisabetta Bugianesi	6
8	Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation 2021 ·Cellular and Molecular Gastroenterology and Hepatology ·Beatrice Foglia, Salvatore Sutti, Stefania Cannito, Chiara Rosso, Marina Maggiora, Riccardo Autelli, Erica Novo, Claudia Bocca, Gianmarco Villano, (unknown), Ramy Younes, Ignazia Tusa, Elisabetta Rovida, Patrizia Pontisso, Elisabetta Bugianesi, Emanuele Albano, Maurizio Parola	18
9	Mechanisms for increased risk of diabetes in chronic liver diseases 2020 ·Liver International ·Gianluca Svegliati‐Baroni, Melania Gaggini, Fabrizia Carli, Chiara Barbieri, (unknown), Ramy Younes, Chiara Rosso, Elisabetta Bugianesi, Amalia Gastaldelli	13
10	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 2020 ·Diagnostic Microbiology and Infectious Disease ·Gian Paolo Caviglia, Antonella Olivero, Alessia Ciancio, Francesco Tandoi, Giulia Troshina, Chiara Rosso, Maria Lorena Abate, Ramy Younes, Davide Giuseppe Ribaldone, Antonina Smedile, Mario Rizzetto, Renato Romagnoli, Giorgio Maria Saracco, Elisabetta Bugianesi	14
11	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease 2020 ·Frontiers in Medicine ·Konstantin Kazankov, Chiara Rosso, Ramy Younes, Angelo Armandi, Hannes Hagström, Holger Jon Møller, Per Stål, Elisabetta Bugianesi, Henning Grønbæk	3
12	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 2020 ·Journal of Clinical Medicine ·Gian Paolo Caviglia, Chiara Rosso, (unknown), Martina Rizzo, (unknown), Maria Lorena Abate, Antonella Olivero, Angelo Armandi, Ester Vanni, Ramy Younes, Sharmila Fagoonee, Rinaldo Pellicano, Marco Astegiano, Giorgio Maria Saracco, Elisabetta Bugianesi, Davide Giuseppe Ribaldone	36
13	Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease 2019 ·International Journal of Molecular Sciences ·Melania Gaggini, Fabrizia Carli, Chiara Rosso, Ramy Younes, Romina D’Aurizio, Elisabetta Bugianesi, Amalia Gastaldelli	26
14	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study 2019 ·Minerva Medica ·Chiara Rosso, Gian Paolo Caviglia, (unknown), Alessia Ciancio, Ramy Younes, Antonella Olivero, Chiara Giordanino, Giulia Troshina, Maria Lorena Abate, Mario Rizzetto, Rinaldo Pellicano, Giorgio Maria Saracco, Elisabetta Bugianesi, Antonina Smedile	12
15	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease 2019 ·Journal of Hepatology ·Chiara Rosso, Konstantin Kazankov, Ramy Younes, Saeed Esmaili, M. Marietti, M. Sacco, Fabrizia Carli, Melania Gaggini, Federico Salomone, Holger Jon Møller, Maria Lorena Abate, Hendrik Vilstrup, Amalia Gastaldelli, Jacob George, Henning Grønbæk, Elisabetta Bugianesi	156
16	NASH in Lean Individuals 2019 ·Seminars in Liver Disease ·Ramy Younes, Elisabetta Bugianesi	171
17	A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD 2018 ·Nature Reviews Gastroenterology & Hepatology ·Ramy Younes, Elisabetta Bugianesi	32
18	Risk factors for arterial hypertension after liver transplantation 2018 ·Journal of the American Society of Hypertension ·Cristina Di Stefano, Ester Vanni, S. Mirabella, Ramy Younes, (unknown), (unknown), (unknown), Valeria Milazzo, Simona Maule, Renato Romagnoli, Mauro Salizzoni, Franco Veglio, Alberto Milan	12
19	Bile acid composition modulate insulin resistance in non-diabetic patients with NAFLD 2018 ·Journal of Hepatology ·Chiara Rosso, Ramy Younes, Mohammed Eslam, (unknown), (unknown), Melania Gaggini, Sally Coulter, Fabrizia Carli, C. Barbieri, Veronica Della Latta, Maria Lorena Abate, Giorgio Maria Saracco, Amalia Gastaldelli, (unknown), Elisabetta Bugianesi	2
20	Should we undertake surveillance for HCC in patients with NAFLD? 2017 ·Journal of Hepatology ·Ramy Younes, Elisabetta Bugianesi	123

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact